Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Foghorn Therapeutics Inc.FHTX · Entity 5820 | Chief Scientific Officer | January 30, 2026 | February 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Foghorn Therapeutics Inc.
Report date January 30, 2026 · Filed February 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.71 · Expires 2036-01-29 | Direct | 300,000 |
Reported balance
After 2026-01-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-30 · Grant · Acquired 300,000 · Balance 300,000 F1: The option vests as to 25% of the underlying shares of common stock on January 30, 2027, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests as to 25% of the underlying shares of common stock on January 30, 2027, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 30, 2026 Filed Feb 2, 2026 21:01 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | GrantStock Option (right to buy) · Derivative | 300,000 | $5.71 Strike: $5.71 | $1,713,000.00 |
DisclosureSEC source: 0001831749-26-000002 · primarydocument.xml · derivative · entry 1 Bellon Steven F. · CIK 0001831749 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2036-01-29 F1 · derivative.exercise_date: The option vests as to 25% of the underlying shares of common stock on January 30, 2027, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter. Read SEC document |
| January 22, 2025 Filed Jan 24, 2025 21:09 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | GrantStock Option (right to buy) · Derivative | 140,000 | $4.37 Strike: $4.37 | $611,800.00 |
DisclosureSEC source: 0001562180-25-000500 · primarydocument.xml · derivative · entry 1 Bellon Steven F. · CIK 0001831749 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 140,000 shares Expires 2035-01-21 F1 · derivative.exercise_date: The option vests as to 25% of the underlying shares of common stock on January 22, 2026, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter. Read SEC document |
| September 09, 2024 Filed Sep 11, 2024 20:00 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | SaleCommon Stock | 20,000 | $9.50 | $190,000.00 |
DisclosureSEC source: 0001562180-24-006767 · primarydocument.xml · nonDerivative · entry 1 Bellon Steven F. · CIK 0001831749 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 101,957 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan that was adopted by the reporting person on March 11, 2024. Read SEC document |
| January 24, 2024 Filed Jan 25, 2024 21:02 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | GrantStock Option (right to buy) · Derivative | 110,000 | $3.06 Strike: $3.06 | $336,600.00 |
DisclosureSEC source: 0001562180-24-000606 · primarydocument.xml · derivative · entry 1 Bellon Steven F. · CIK 0001831749 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 110,000 shares Expires 2034-01-23 F1 · derivative.exercise_date: The option vests as to 25% of the underlying shares of common stock on January 24, 2025, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter. Read SEC document |
| January 26, 2023 Filed Jan 30, 2023 22:03 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $8.38 | $0.00 |
DisclosureSEC source: 0001562180-23-000726 · primarydocument.xml · derivative · entry 1 Bellon Steven F. · CIK 0001831749 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2033-01-25 F1 · derivative.exercise_date: The option vests as to 25% of the underlying shares of common stock on January 26, 2024, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter. Read SEC document |
| August 11, 2022 Filed Aug 15, 2022 22:15 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | Exercise / conversionStock Options (Right to buy) · Derivative | 1,858 | $0.00 Strike: $3.72 | $0.00 |
DisclosureSEC source: 0001562180-22-006087 · primarydocument.xml · derivative · entry 3 Bellon Steven F. · CIK 0001831749 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,716 Underlying: Common Stock · 1,858 shares Expires 2029-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vested as to 25% of the underlying shares of common stock on January 30, 2020, the first anniversary of the of the vesting commencement date, and at a rate of 6.25% of the underlying shares thereafter on the first day of each calendar quarter following such first anniversary until the option is fully vested. Read SEC document |
| August 11, 2022 Filed Aug 15, 2022 22:15 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | Exercise / conversionCommon Stock | 1,858 | $3.72 | $6,911.76 |
DisclosureSEC source: 0001562180-22-006087 · primarydocument.xml · nonDerivative · entry 1 Bellon Steven F. · CIK 0001831749 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,957 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 25, 2022 Filed May 27, 2022 20:10 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | Exercise / conversionStock Options (Right to buy) · Derivative | 3,717 | $0.00 Strike: $3.72 | $0.00 |
DisclosureSEC source: 0001562180-22-004545 · primarydocument.xml · derivative · entry 5 Bellon Steven F. · CIK 0001831749 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,574 Underlying: Common Stock · 3,717 shares Expires 2029-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested as to 25% of the underlying shares of common stock on January 30, 2020, the first anniversary of the of the vesting commencement date, and at a rate of 6.25% of the underlying shares thereafter on the first day of each calendar quarter following such first anniversary until the option is fully vested. Read SEC document |
| May 25, 2022 Filed May 27, 2022 20:10 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | Exercise / conversionStock Options (Right to buy) · Derivative | 675 | $0.00 Strike: $0.73 | $0.00 |
DisclosureSEC source: 0001562180-22-004545 · primarydocument.xml · derivative · entry 4 Bellon Steven F. · CIK 0001831749 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 675 shares Expires 2028-01-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vested at a rate of 6.25% of the underlying shares beginning on April 1, 2018 and thereafter on the first day of each calendar quarter until the option was fully vested. Read SEC document |
| May 25, 2022 Filed May 27, 2022 20:10 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | Exercise / conversionCommon Stock | 3,717 | $3.72 | $13,827.24 |
DisclosureSEC source: 0001562180-22-004545 · primarydocument.xml · nonDerivative · entry 2 Bellon Steven F. · CIK 0001831749 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,099 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 25, 2022 Filed May 27, 2022 20:10 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | Exercise / conversionCommon Stock | 675 | $0.73 | $492.75 |
DisclosureSEC source: 0001562180-22-004545 · primarydocument.xml · nonDerivative · entry 1 Bellon Steven F. · CIK 0001831749 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,382 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 26, 2022 Filed Jan 28, 2022 21:27 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | GrantStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $14.87 | $0.00 |
DisclosureSEC source: 0001562180-22-000750 · primarydocument.xml · derivative · entry 1 Bellon Steven F. · CIK 0001831749 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2032-01-25 F1 · derivative.exercise_date: The option vested as to 25% of the underlying shares of common stock on January 26, 2023, the first anniversary of the of the vesting commencement date, and at a rate of 6.25% of the underlying shares thereafter on the first day of each calendar quarter following such first anniversary until the option is fully vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.